CORZNasdaqFinance ServicesFiscal year ends December 31Also trades as CORZR, CORZW, CORZZ
Core Scientific, Inc./tx
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 28, 2026
$13.73+0.25 (+1.85%)
Close on Oct 19, 2026
- Market cap
- $4.47B
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2019 to 2025
Gross margin
11.9%−3.7 pts over 5 years
Operating margin
-77.0%−66.5 pts over 5 years
Net margin
-90.5%−70.2 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | -37.5% | -20.7% | +39.5% | – | |
| Gross profit | -68.7% | +65.2% | +32.2% | – |
Returns and balance sheet
7 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2019 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | -12.5% | 30.3% | |
| Return on assets | – | – | -15.1% | |
| Current ratio | – | – | 1.15 | |
| Debt to equity | – | – | -1.10 | |
| Net debt to EBITDA | – | – | -4.24× | |
| Capex to revenue | – | 0.0% | 228.5% | |
| Diluted shares | – | 158M | 318M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Core Scientific generated $648.18M from operations and spent $1.26B on capital expenditure, dividends and share buybacks. 97% of that went back into the business.
Generated
$648.18M
Used
$1.26B
Capital expenditure$1.22B97%Dividends$00%Share buybacks$31.65M3%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-90.5%
×Asset turnover0.17×
×Equity multiplier-2.01×
=Return on equity, FY202530.3%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -90.5% | 0.17× | -2.01× | 30.3% |
| FY2024 | -281.6% | 0.47× | -1.42× | 186.7% |
| FY2023 | -49.1% | 0.66× | -1.51× | 49.0% |
| FY2022 | -335.2% | 0.39× | 3.48× | -460.7% |
| FY2021 | 8.7% | 0.45× | 1.70× | 6.6% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
4of 9 tests passed in fiscal 2025. Scores of 7 to 9 are usually read as strong.
- ProfitableNet income above zero-$288.62M
- Cash generatingOperating cash flow above zero$278.25M
- Return on assets improvedROA up on the prior year-201.9% → -19.6%
- Earnings backed by cashOperating cash flow above net income$278.25M vs -$288.62M
- Less leverageLong-term debt to assets fell72.8% → 45.2%
- Better liquidityCurrent ratio rose6.72 → 1.15
- No dilutionShare count did not rise256M → 318M
- Gross margin improvedGross margin up on the prior year23.71% → 11.88%
- More efficientAsset turnover rose0.72 → 0.22